Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Pediatric Drugs
Erschienen in: Pediatric Drugs 2/2016

01.04.2016 | Therapy in Practice

Optimizing the Use of Antibacterial Agents in the Neonatal Period

verfasst von: Joseph B. Cantey

Erschienen in: Pediatric Drugs | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Antibiotics are invaluable in the management of neonatal infections. However, overuse or misuse of antibiotics in neonates has been associated with adverse outcomes, including increased risk for future infection, necrotizing enterocolitis, and mortality. Strategies to optimize the use of antibiotics in the neonatal intensive care unit include practicing effective infection prevention, improving the diagnostic evaluation and empiric therapy for suspected infections, timely adjustment of therapy as additional information becomes available, and treating proven infections with an effective, narrow-spectrum agent for the minimum effective duration. Antibiotic stewardship programs provide support for these strategies but require the participation and input of neonatologists as stakeholders to be most effective.
Literatur
1.
Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162–72.PubMedCrossRef
2.
Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 Pt 1):285–91.PubMedCrossRef
3.
Stoll BJ, Hansen NI, Sanchez PJ, Faix RG, Poindexter BB, Van Meurs KP, et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics. 2011;127(5):817–26.PubMedPubMedCentralCrossRef
4.
Wirtschafter DD, Padilla G, Suh O, Wan K, Trupp D, Fayard EE. Antibiotic use for presumed neonatally acquired infections far exceeds that for central line-associated blood stream infections: an exploratory critique. J Perinatol. 2011;31(8):514–8.PubMedCrossRef
5.
Cantey JB, Wozniak PS, Sanchez PJ. Prospective surveillance of antibiotic use in the neonatal intensive care unit: results from the SCOUT Study. Pediatr Infect Dis J. 2015;34(3):267–72.PubMedCrossRef
6.
Patel SJ, Oshodi A, Prasad P, Delamora P, Larson E, Zaoutis T, et al. Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance. Pediatr Infect Dis J. 2009;28(12):1047–51.PubMedPubMedCentralCrossRef
7.
Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006;117(6):1979–87.PubMedCrossRef
8.
Schulman J, Dimand RJ, Lee HC, Duenas GV, Bennett MV, Gould JB. Neonatal intensive care unit antibiotic use. Pediatrics. 2015;135(5):826–33.PubMedCrossRef
9.
Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin DK Jr, Smith PB, et al. Medication use in the neonatal intensive care unit. Am J Perinatol. 2014;31(9):811–21.PubMedPubMedCentralCrossRef
10.
11.
Shah P, Nathan E, Doherty D, Patole S. Prolonged exposure to antibiotics and its associations in extremely preterm neonates: the Western Australian experience. J Matern Fetal Neonatal Med. 2013;26(17):1710–4.PubMedCrossRef
12.
Mai V, Young CM, Ukhanova M, Wang X, Sun Y, Casella G, et al. Fecal microbiota in premature infants prior to necrotizing enterocolitis. PLoS One. 2011;6(6):e20647.PubMedPubMedCentralCrossRef
13.
Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr. 2011;159(5):720–5.PubMedPubMedCentralCrossRef
14.
Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sanchez PJ, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics. 2009;123(1):58–66.PubMedPubMedCentralCrossRef
15.
Saiman L, Ludington E, Dawson JD, Patterson JE, Rangel-Frausto S, Wiblin RT, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J. 2001;20(12):1119–24.PubMedCrossRef
16.
Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr. 2011;159(3):392–7.PubMedPubMedCentralCrossRef
17.
Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK Jr. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118(2):717–22.PubMedCrossRef
18.
Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N, et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe. 2015;17(5):704–15.PubMedCrossRef
19.
Saari A, Virta LJ, Sankilampi U, Dunkel L, Saxen H. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics. 2015;135(4):617–26.PubMedCrossRef
20.
Wegienka G, Havstad S, Zoratti EM, Kim H, Ownby DR, Johnson CC. Combined effects of prenatal medication use and delivery type are associated with eczema at age 2 years. Clin Exp Allergy. 2015;45(3):660–8.PubMedPubMedCentralCrossRef
21.
de Man P, Verhoeven BA, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000;355(9208):973–8.PubMedCrossRef
22.
Cantey JB, Milstone AM. Bloodstream infections: epidemiology and resistance. Clin Perinatol. 2015;42(1):1–16 (vii).PubMedCrossRef
23.
Bizzarro MJ, Gallagher PG. Antibiotic-resistant organisms in the neonatal intensive care unit. Semin Perinatol. 2007;31(1):26–32.PubMedCrossRef
24.
Tsai MH, Chu SM, Hsu JF, Lien R, Huang HR, Chiang MC, et al. Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU. Pediatrics. 2014;133(2):e322–9.PubMedCrossRef
25.
Huang Y, Zhuang S, Du M. Risk factors of nosocomial infection with extended-spectrum beta-lactamase-producing bacteria in a neonatal intensive care unit in China. Infection. 2007;35(5):339–45.PubMedCrossRef
26.
Toltzis P. Colonization with antibiotic-resistant Gram-negative bacilli in the neonatal intensive care unit. Minerva Pediatr. 2003;55(5):385–93.PubMed
27.
Cantey JB, Patel SJ. Antimicrobial stewardship in the NICU. Infect Dis Clin N Am. 2014;28(2):247–61.CrossRef
28.
Azab SF, Sherbiny HS, Saleh SH, Elsaeed WF, Elshafiey MM, Siam AG, et al. Reducing ventilator-associated pneumonia in neonatal intensive care unit using “VAP prevention Bundle”: a cohort study. BMC Infect Dis. 2015;15:314.PubMedPubMedCentralCrossRef
29.
Fisher D, Cochran KM, Provost LP, Patterson J, Bristol T, Metzguer K, et al. Reducing central line-associated bloodstream infections in North Carolina NICUs. Pediatrics. 2013;132(6):e1664–71.PubMedCrossRef
30.
Rosenthal VD, Duenas L, Sobreyra-Oropeza M, Ammar K, Navoa-Ng JA, de Casares AC, et al. Findings of the International Nosocomial Infection Control Consortium (INICC), part III: effectiveness of a multidimensional infection control approach to reduce central line-associated bloodstream infections in the neonatal intensive care units of 4 developing countries. Infect Control Hosp Epidemiol. 2013;34(3):229–37.PubMed
31.
Rosenthal VD, Rodriguez-Calderon ME, Rodriguez-Ferrer M, Singhal T, Pawar M, Sobreyra-Oropeza M, et al. Findings of the International Nosocomial Infection Control Consortium (INICC), part II: impact of a multidimensional strategy to reduce ventilator-associated pneumonia in neonatal intensive care units in 10 developing countries. Infect Control Hosp Epidemiol. 2012;33(7):704–10.PubMedCrossRef
32.
Schulman J, Stricof R, Stevens TP, Horgan M, Gase K, Holzman IR, et al. Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists. Pediatrics. 2011;127(3):436–44.PubMedCrossRef
33.
Greenberg RG, Cochran KM, Smith PB, Edson BS, Schulman J, Lee HC, et al. Effect of catheter dwell time on risk of central line-associated bloodstream infection in infants. Pediatrics. 2015;136(6):1080–6.PubMedCrossRef
34.
Wojkowska-Mach J, Rozanska A, Borszewska-Kornacka M, Domanska J, Gadzinowski J, Gulczynska E, et al. Necrotising enterocolitis in preterm infants: epidemiology and antibiotic consumption in the Polish neonatology network neonatal intensive care units in 2009. PLoS One. 2014;9(3):e92865.PubMedPubMedCentralCrossRef
35.
Patel AL, Trivedi S, Bhandari NP, Ruf A, Scala CM, Witowitch G, et al. Reducing necrotizing enterocolitis in very low birth weight infants using quality-improvement methods. J Perinatol. 2014;34(11):850–7.PubMedPubMedCentralCrossRef
36.
Patole SK, de Klerk N. Impact of standardised feeding regimens on incidence of neonatal necrotising enterocolitis: a systematic review and meta-analysis of observational studies. Arch Dis Child Fetal Neonatal Ed. 2005;90(2):F147–51.PubMedPubMedCentralCrossRef
37.
Sisk PM, Lovelady CA, Dillard RG, Gruber KJ, O’Shea TM. Early human milk feeding is associated with a lower risk of necrotizing enterocolitis in very low birth weight infants. J Perinatol. 2007;27(7):428–33.PubMedCrossRef
38.
Cristofalo EA, Schanler RJ, Blanco CL, Sullivan S, Trawoeger R, Kiechl-Kohlendorfer U, et al. Randomized trial of exclusive human milk versus preterm formula diets in extremely premature infants. J Pediatr. 2013;163(6):1592–5 (e1).PubMedCrossRef
39.
Mukerji A, Narciso J, Moore C, McGeer A, Kelly E, Shah V. An observational study of the hand hygiene initiative: a comparison of preintervention and postintervention outcomes. BMJ Open. 2013;3(5):e003018.PubMedPubMedCentralCrossRef
40.
Harris AD, Pineles L, Belton B, Johnson JK, Shardell M, Loeb M, et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. JAMA. 2013;310(15):1571–80.PubMedPubMedCentral
41.
Huskins WC, Huckabee CM, O’Grady NP, Murray P, Kopetskie H, Zimmer L, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med. 2011;364(15):1407–18.PubMedPubMedCentralCrossRef
42.
Kaufman DA, Blackman A, Conaway MR, Sinkin RA. Nonsterile glove use in addition to hand hygiene to prevent late-onset infection in preterm infants: randomized clinical trial. JAMA Pediatr. 2014;168(10):909–16.PubMedCrossRef
43.
Cantey JB, Ronchi A, Sanchez PJ. Spreading the benefits of infection prevention in the Neonatal Intensive Care Unit. JAMA Pediatr. 2015;169(12):1089–91.PubMedCrossRef
44.
Rybczynska H, Melander E, Johansson H, Lundberg F. Efficacy of a once-a-week screening programme to control extended-spectrum beta-lactamase-producing bacteria in a neonatal intensive care unit. Scand J Infect Dis. 2014;46(6):426–32.PubMedCrossRef
45.
Macnow T, O’Toole D, DeLaMora P, Murray M, Rivera K, Whittier S, et al. Utility of surveillance cultures for antimicrobial resistant organisms in infants transferred to the neonatal intensive care unit. Pediatr Infect Dis J. 2013;32(12):e443–50.PubMedCrossRef
46.
Milstone AM, Maragakis LL, Carroll KC, Perl TM. Targeted surveillance to identify children colonized with vancomycin-resistant Enterococcus in the pediatric intensive care unit. Infect Control Hosp Epidemiol. 2010;31(1):95–8.PubMedCrossRef
47.
Popoola VO, Budd A, Wittig SM, Ross T, Aucott SW, Perl TM, et al. Methicillin-resistant Staphylococcus aureus transmission and infections in a neonatal intensive care unit despite active surveillance cultures and decolonization: challenges for infection prevention. Infect Control Hosp Epidemiol. 2014;35(4):412–8.PubMedPubMedCentralCrossRef
48.
Chapman AK, Aucott SW, Gilmore MM, Advani S, Clarke W, Milstone AM. Absorption and tolerability of aqueous chlorhexidine gluconate used for skin antisepsis prior to catheter insertion in preterm neonates. J Perinatol. 2013;33(10):768–71.PubMedPubMedCentralCrossRef
49.
Bringue Espuny X, Soria X, Sole E, Garcia J, Marco JJ, Ortega J, et al. Chlorhexidine-methanol burns in two extreme preterm newborns. Pediatr Dermatol. 2010;27(6):676–8.
50.
Johnson RC, Schlett CD, Crawford K, Lanier JB, Merrell DS, Ellis MW. Recurrent methicillin-resistant Staphylococcus aureus cutaneous abscesses and selection of reduced chlorhexidine susceptibility during chlorhexidine use. J Clin Microbiol. 2015;53(11):3677–82.PubMedCrossRef
51.
Ichikawa K, Fujiwara T, Nakayama T. Effectiveness of home visits in pregnancy as a public health measure to improve birth outcomes. PLoS One. 2015;10(9):e0137307.PubMedPubMedCentralCrossRef
52.
McLaughlin FJ, Altemeier WA, Christensen MJ, Sherrod KB, Dietrich MS, Stern DT. Randomized trial of comprehensive prenatal care for low-income women: effect on infant birth weight. Pediatrics. 1992;89(1):128–32.PubMed
53.
Shah NR, Bracken MB. A systematic review and meta-analysis of prospective studies on the association between maternal cigarette smoking and preterm delivery. Am J Obstet Gynecol. 2000;182(2):465–72.PubMedPubMedCentralCrossRef
54.
Sangkomkamhang US, Lumbiganon P, Prasertcharoensuk W, Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst Rev. 2015;2:CD006178.PubMed
55.
Dodd JM, Jones L, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev. 2013;7:CD004947.PubMed
56.
Bekhof J, Reitsma JB, Kok JH, Van Straaten IH. Clinical signs to identify late-onset sepsis in preterm infants. Eur J Pediatr. 2013;172(4):501–8.PubMedCrossRef
57.
Fischer JE. Physicians’ ability to diagnose sepsis in newborns and critically ill children. Pediatr Crit Care Med. 2005;6(3 Suppl):S120–5.PubMedCrossRef
58.
Ottolini MC, Lundgren K, Mirkinson LJ, Cason S, Ottolini MG. Utility of complete blood count and blood culture screening to diagnose neonatal sepsis in the asymptomatic at risk newborn. Pediatr Infect Dis J. 2003;22(5):430–4.PubMed
59.
DiGeronimo RJ. Lack of efficacy of the urine culture as part of the initial workup of suspected neonatal sepsis. Pediatr Infect Dis J. 1992;11(9):764–6.PubMedCrossRef
60.
Visser VE, Hall RT. Urine culture in the evaluation of suspected neonatal sepsis. J Pediatr. 1979;94(4):635–8.PubMedCrossRef
61.
Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128(3):595–610.CrossRef
62.
Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants. Pediatrics. 2004;113(5):1181–6.PubMedCrossRef
63.
Flidel-Rimon O, Leibovitz E, Eventov Friedman S, Juster-Reicher A, Shinwell ES. Is lumbar puncture (LP) required in every workup for suspected late-onset sepsis in neonates? Acta Paediatr. 2011;100(2):303–4.
64.
Kliegman RM, Walsh MC. The incidence of meningitis in neonates with necrotizing enterocolitis. Am J Perinatol. 1987;4(3):245–8.PubMedCrossRef
65.
Hendricks-Munoz KD, Shapiro DL. The role of the lumbar puncture in the admission sepsis evaluation of the premature infant. J Perinatol. 1990;10(1):60–4.PubMed
66.
Weiss MG, Ionides SP, Anderson CL. Meningitis in premature infants with respiratory distress: role of admission lumbar puncture. J Pediatr. 1991;119(6):973–5.PubMedCrossRef
67.
Dietzman DE, Fischer GW, Schoenknecht FD. Neonatal Escherichia coli septicemia: bacterial counts in blood. J Pediatr. 1974;85(1):128–30.PubMedCrossRef
68.
Schelonka RL, Chai MK, Yoder BA, Hensley D, Brockett RM, Ascher DP. Volume of blood required to detect common neonatal pathogens. J Pediatr. 1996;129(2):275–8.PubMedCrossRef
69.
Connell TG, Rele M, Cowley D, Buttery JP, Curtis N. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children’s hospital. Pediatrics. 2007;119(5):891–6.PubMedCrossRef
70.
Kellogg JA, Ferrentino FL, Goodstein MH, Liss J, Shapiro SL, Bankert DA. Frequency of low level bacteremia in infants from birth to two months of age. Pediatr Infect Dis J. 1997;16(4):381–5.PubMedCrossRef
71.
Polin RA, Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics. 2012;129(5):1006–15.PubMedCrossRef
72.
Sarkar S, Bhagat I, DeCristofaro JD, Wiswell TE, Spitzer AR. A study of the role of multiple site blood cultures in the evaluation of neonatal sepsis. J Perinatol. 2006;26(1):18–22.PubMedCrossRef
73.
Seybold U, Reichardt C, Halvosa JS, Blumberg HM. Clonal diversity in episodes with multiple coagulase-negative Staphylococcus bloodstream isolates suggesting frequent contamination. Infection. 2009;37(3):256–60.PubMedCrossRef
74.
Struthers S, Underhill H, Albersheim S, Greenberg D, Dobson S. A comparison of two versus one blood culture in the diagnosis and treatment of coagulase-negative staphylococcus in the neonatal intensive care unit. J Perinatol. 2002;22(7):547–9.PubMedCrossRef
75.
Healy CM, Baker CJ, Palazzi DL, Campbell JR, Edwards MS. Distinguishing true coagulase-negative Staphylococcus infections from contaminants in the neonatal intensive care unit. J Perinatol. 2013;33(1):52–8.PubMedCrossRef
76.
77.
Willson DF, Conaway M, Kelly R, Hendley JO. The lack of specificity of tracheal aspirates in the diagnosis of pulmonary infection in intubated children. Pediatr Crit Care Med. 2014;15(4):299–305.PubMedCrossRef
78.
Willson DF, Kirby A, Kicker JS. Respiratory secretion analyses in the evaluation of ventilator-associated pneumonia: a survey of current practice in pediatric critical care. Pediatr Crit Care Med. 2014;15(8):715–9.PubMedCrossRef
79.
Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006;355(25):2619–30.CrossRef
80.
Mikhael M, Brown LS, Rosenfeld CR. Serial neutrophil values facilitate predicting the absence of neonatal early-onset sepsis. J Pediatr. 2014;164(3):522–8 (e1–3).PubMedCrossRef
81.
Srinivasan L, Harris MC. New technologies for the rapid diagnosis of neonatal sepsis. Curr Opin Pediatr. 2012;24(2):165–71.PubMedCrossRef
82.
Bhandari V. Effective biomarkers for diagnosis of neonatal sepsis. J Pediatr Infect Dis Soc. 2014;3(3):234–45.CrossRef
83.
Ng PC, Ma TP, Lam HS. The use of laboratory biomarkers for surveillance, diagnosis and prediction of clinical outcomes in neonatal sepsis and necrotising enterocolitis. Arch Dis Child Fetal Neonatal Ed. 2015;100(5):F448–52.PubMedCrossRef
84.
Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease: I. Reference values for neutrophilic cells. J Pediatr. 1979;95(1):89–98.PubMedCrossRef
85.
Cantey JB, Sanchez PJ. Prolonged antibiotic therapy for “culture-negative” sepsis in preterm infants: it’s time to stop! J Pediatr. 2011;159(5):707–8.PubMedCrossRef
86.
Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis. 2011;52(10):1232–40.PubMedCrossRef
87.
Cantey JB, Sreeramoju P, Jaleel M, Trevino S, Gander R, Hynan LS, et al. Prompt control of an outbreak caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit. J Pediatr. 2013;163(3):672–9 e1–3.PubMedCrossRef
88.
Cilo BD, Agca H, Efe K, Sinirtas M, Celebi S, Ozkan H, et al. Investigation of vancomycin resistant Enterococcus faecium outbreak in neonatal intensive care unit. Int J Clin Exp Med. 2014;7(12):5342–7.PubMedPubMedCentral
89.
Park C, Nichols M, Schrag SJ. Two cases of invasive vancomycin-resistant group B streptococcus infection. N Engl J Med. 2014;370(9):885–6.PubMedCrossRef
90.
Heideking M, Lander F, Hufnagel M, Pfeifer Y, Wicker E, Krause G, et al. Antibiotic susceptibility profiles of neonatal invasive isolates of Escherichia coli from a 2-year nationwide surveillance study in Germany, 2009–2010. Eur J Clin Microbiol Infect Dis. 2013;32(9):1221–3.PubMedCrossRef
91.
Wade KC, Benjamin DK. Clinical pharmacology of antiinfective drugs. In: Wilson CB, Nizet V, Maldonado YA, Remington JS, Klein JO, editors. Remington and Klein’s infectious diseases of the fetus and newborn infant. 8th ed. Philadelphia: Elsevier; 2016.
92.
Nelson’s Pediatric Antimicrobial Therapy. 21st ed. Elk Grove Village (IL): American Academy of Pediatrics; 2015.
93.
Shane AL, Hansen NI, Stoll BJ, Bell EF, Sanchez PJ, Shankaran S, et al. Methicillin-resistant and susceptible Staphylococcus aureus bacteremia and meningitis in preterm infants. Pediatrics. 2012;129(4):e914–22.PubMedPubMedCentralCrossRef
94.
Ericson JE, Popoola VO, Smith PB, Benjamin DK, Fowler VG, Benjamin DK Jr, et al. Burden of invasive Staphylococcus aureus infections in hospitalized infants. JAMA Pediatr. 2015;169(12):1105–11.PubMedCrossRef
95.
Chiu CH, Michelow IC, Cronin J, Ringer SA, Ferris TG, Puopolo KM. Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit. Pediatr Infect Dis J. 2011;30(4):273–8.PubMedCrossRef
96.
Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52(1):192–7.PubMedPubMedCentralCrossRef
97.
Huang YC, Chou YH, Su LH, Lien RI, Lin TY. Methicillin-resistant Staphylococcus aureus colonization and its association with infection among infants hospitalized in neonatal intensive care units. Pediatrics. 2006;118(2):469–74.PubMedCrossRef
98.
Qu Y, Daley AJ, Istivan TS, Garland SM, Deighton MA. Antibiotic susceptibility of coagulase-negative staphylococci isolated from very low birth weight babies: comprehensive comparisons of bacteria at different stages of biofilm formation. Ann Clin Microbiol Antimicrob. 2010;9:16.PubMedPubMedCentralCrossRef
99.
Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988–1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics. 2000;106(6):1387–90.PubMedCrossRef
100.
Lawrence SL, Roth V, Slinger R, Toye B, Gaboury I, Lemyre B. Cloxacillin versus vancomycin for presumed late-onset sepsis in the Neonatal Intensive Care Unit and the impact upon outcome of coagulase negative staphylococcal bacteremia: a retrospective cohort study. BMC Pediatr. 2005;5:49.PubMedPubMedCentralCrossRef
101.
Hemels MA, van den Hoogen A, Verboon-Maciolek MA, Fleer A, Krediet TG. A seven-year survey of management of coagulase-negative staphylococcal sepsis in the neonatal intensive care unit: vancomycin may not be necessary as empiric therapy. Neonatology. 2011;100(2):180–5.PubMedCrossRef
102.
Zhou Y, Shan G, Sodergren E, Weinstock G, Walker WA, Gregory KE. Longitudinal analysis of the premature infant intestinal microbiome prior to necrotizing enterocolitis: a case-control study. PLoS One. 2015;10(3):e0118632.PubMedPubMedCentralCrossRef
103.
104.
Greenwood C, Morrow AL, Lagomarcino AJ, Altaye M, Taft DH, Yu Z, et al. Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. J Pediatr. 2014;165(1):23–9.PubMedPubMedCentralCrossRef
105.
Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2015;2:CD007137.PubMed
106.
Dilli D, Aydin B, Fettah ND, Ozyazici E, Beken S, Zenciroglu A, et al. The propre-save study: effects of probiotics and prebiotics alone or combined on necrotizing enterocolitis in very low birth weight infants. J Pediatr. 2015;166(3):545–51 (e1).PubMedCrossRef
107.
Vallabhaneni S, Walker TA, Lockhart SR, Ng D, Chiller T, Melchreit R, et al. Notes from the field: fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement—Connecticut, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(6):155–6.PubMed
108.
Abrahamsson TR. Not all probiotic strains prevent necrotising enterocolitis in premature infants. Lancet (Epub 25 Nov 2015).
109.
Liem TB, Krediet TG, Fleer A, Egberts TC, Rademaker CM. Variation in antibiotic use in neonatal intensive care units in the Netherlands. J Antimicrob Chemother. 2010;65(6):1270–5.PubMedCrossRef
110.
Shah D, Sinn JK. Antibiotic regimens for the empirical treatment of newborn infants with necrotising enterocolitis. Cochrane Database Syst Rev. 2012;8:CD007448.PubMed
111.
Faix RG, Polley TZ, Grasela TH. A randomized, controlled trial of parenteral clindamycin in neonatal necrotizing enterocolitis. J Pediatr. 1988;112(2):271–7.PubMedCrossRef
112.
Hansen TN, Ritter DA, Speer ME, Kenny JD, Rudolph AJ. A randomized, controlled study of oral gentamicin in the treatment of neonatal necrotizing enterocolitis. J Pediatr. 1980;97(5):836–9.PubMedCrossRef
113.
Autmizguine J, Hornik CP, Benjamin DK Jr, Laughon MM, Clark RH, Cotten CM, et al. Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants. Pediatrics. 2015;135(1):e117–25.PubMedPubMedCentralCrossRef
114.
Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin N Am. 1986;33(1):179–201.
115.
Kurlat I, Stoll BJ, McGowan JE Jr. Time to positivity for detection of bacteremia in neonates. J Clin Microbiol. 1989;27(5):1068–71.PubMedPubMedCentral
116.
Biondi EA, Mischler M, Jerardi KE, Statile AM, French J, Evans R, et al. Blood culture time to positivity in febrile infants with bacteremia. JAMA Pediatr. 2014;168(9):844–9.PubMedCrossRef
117.
Jardine L, Davies MW, Faoagali J. Incubation time required for neonatal blood cultures to become positive. J Paediatr Child Health. 2006;42(12):797–802.PubMedCrossRef
118.
Cantey JB, Lopez-Medina E, Nguyen S, Doern C, Garcia C. Empiric antibiotics for serious bacterial infection in young infants: opportunities for stewardship. Pediatr Emerg Care. 2015;31(8):568–71.PubMedCrossRef
119.
Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2014;1:CD003344.PubMed
120.
Cordero L, Ayers LW. Duration of empiric antibiotics for suspected early-onset sepsis in extremely low birth weight infants. Infect Control Hosp Epidemiol. 2003;24(9):662–6.PubMedCrossRef
121.
Spitzer AR, Kirkby S, Kornhauser M. Practice variation in suspected neonatal sepsis: a costly problem in neonatal intensive care. J Perinatol. 2005;25(4):265–9.PubMedCrossRef
122.
Wynn JL, Wong HR, Shanley TP, Bizzarro MJ, Saiman L, Polin RA. Time for a neonatal-specific consensus definition for sepsis. Pediatr Crit Care Med. 2014;15(6):523–8.PubMedPubMedCentralCrossRef
123.
Langley JM, Bradley JS. Defining pneumonia in critically ill infants and children. Pediatr Crit Care Med. 2005;6(3 Suppl):S9–13.PubMedCrossRef
124.
Shani L, Weitzman D, Melamed R, Zmora E, Marks K. Risk factors for early sepsis in very low birth weight neonates with respiratory distress syndrome. Acta Paediatr. 2008;97(1):12–5.PubMedCrossRef
125.
Weintraub AS, Cadet CT, Perez R, DeLorenzo E, Holzman IR, Stroustrup A. Antibiotic use in newborns with transient tachypnea of the newborn. Neonatology. 2013;103(3):235–40.PubMedCrossRef
126.
Ronchi A, Michelow IC, Chapin KC, Bliss JM, Pugni L, Mosca F, et al. Viral respiratory tract infections in the neonatal intensive care unit: the VIRIoN-I study. J Pediatr. 2014;165(4):690–6.PubMedCrossRef
127.
Bennett NJ, Tabarani CM, Bartholoma NM, Wang D, Huang D, Riddell SW, et al. Unrecognized viral respiratory tract infections in premature infants during their birth hospitalization: a prospective surveillance study in two neonatal intensive care units. J Pediatr. 2012;161(5):814–8.PubMedPubMedCentralCrossRef
128.
Kidszun A, Hansmann A, Winter J, Grondahl B, Knuf M, Weise K, et al. Detection of respiratory viral infections in neonates treated for suspicion of nosocomial bacterial sepsis: a feasibility study. Pediatr Infect Dis J. 2014;33(1):102–4.PubMedCrossRef
129.
Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet. 2009;48(2):71–88.PubMedCrossRef
130.
de Hoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43(7):417–40.PubMedCrossRef
131.
Butterfield JM, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother. 2011;55(9):4277–82.PubMedPubMedCentralCrossRef
132.
Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;45(11):1077–97.PubMedCrossRef
133.
McClary JD. Principles of drug use in the fetus and neonate. In: Martin RJ, Fanaroff AA, Walsh MC, editors. Fanaroff and Martin’s neonatal-perinatal medicine. 10th ed. Philadelphia (PA): Elsevier; 2015.
134.
Wang J, Edginton AN, Avant D, Burckart GJ. Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling. J Clin Pharmacol. 2015;55(10):1175–83.PubMedCrossRef
135.
Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J. 2003;22(9 Suppl):S153–7.PubMedCrossRef
136.
Gostelow M, Gonzalez D, Smith PB, Cohen-Wolkowiez M. Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol. 2014;7(3):327–40.PubMedPubMedCentralCrossRef
137.
Principi N, Caironi M, Venturini F, Pani L, Esposito S. Daptomycin in paediatrics: current knowledge and the need for future research. J Antimicrob Chemother. 2015;70(3):643–8.PubMedCrossRef
138.
Ward RM, Kern SE. Clinical trials in neonates: a therapeutic imperative. Clin Pharmacol Ther. 2009;86(6):585–7.PubMedCrossRef
139.
O’Hara K, Wright IM, Schneider JJ, Jones AL, Martin JH. Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. Br J Clin Pharmacol. 2015;80(6):1281–8.PubMedCrossRef
140.
Leroux S, Turner MA, Guellec CB, Hill H, van den Anker JN, Kearns GL, et al. Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design. Clin Pharmacokinet. 2015;54(12):1273–85.PubMedCrossRef
141.
Claassen K, Thelen K, Coboeken K, Gaub T, Lippert J, Allegaert K, et al. Development of a physiologically-based pharmacokinetic model for preterm neonates: evaluation with in vivo data. Curr Pharm Des. 2015;21(39):5688–98.PubMedCrossRef
142.
Smits A, De Cock RF, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CA. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob Agents Chemother. 2015;59(10):6344–51.PubMedCrossRef
143.
De Cock RF, Allegaert K, Brussee JM, Sherwin CM, Mulla H, de Hoog M, et al. Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res. 2014;31(10):2643–54.PubMedPubMedCentralCrossRef
144.
US FDA. Food and Drug Administration Safety and Innovation Act. Bethesda (MD): US FDA; 2012. p. 933.
145.
The Sanford guide to antimicrobial therapy 2015. 45th ed. London: Ingram; 2015.
146.
MacGowan A. Revisiting beta-lactams: PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol. 2011;11(5):470–6.PubMedCrossRef
147.
Smuszkiewicz P, Szalek E, Tomczak H, Grzeskowiak E. Continuous infusion of antibiotics in critically ill patients. Curr Clin Pharmacol. 2013;8(1):13–24.PubMed
148.
Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006;40(2):219–23.PubMedCrossRef
149.
Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents. 2006;28(2):122–7.PubMedCrossRef
150.
Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al. A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med. 2015;192(11):1298–305.PubMedCrossRef
151.
Walker MC, Lam WM, Manasco KB. Continuous and extended infusions of beta-lactam antibiotics in the pediatric population. Ann Pharmacother. 2012;46(11):1537–46.PubMedCrossRef
152.
Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):e155–63.PubMedPubMedCentralCrossRef
153.
Bhongsatiern JJJ, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, et al. Evaluation of vancomycin use in late-onset neonatal sepsis using the area under the concentration-time curve to the minimum inhibitory concentration ≥400 target. Ther Drug Monit. 2015;37(6):756–65.PubMedCrossRef
154.
Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J. 2013;32(10):1077–9.PubMedCrossRef
155.
Sinkeler FS, de Haan TR, Hodiamont CJ, Bijleveld YA, Pajkrt D, Mathot RA. Inadequate vancomycin therapy in term and preterm neonates: a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations. BMC Pediatr. 2014;14:193.PubMedPubMedCentralCrossRef
156.
Petrie K, O’Brien C, Bhushan S, Tonna A. Neonatal vancomycin trough level audit using British National Formulary for Children dosing. Arch Dis Child Fetal Neonatal Ed. 2015;100(3):F278–9.PubMedCrossRef
157.
Butin M, Rasigade JP, Martins-Simoes P, Meugnier H, Lemriss H, Goering RV, et al. Wide geographical dissemination of the multiresistant Staphylococcus capitis NRCS: a clone in neonatal intensive-care units. Clin Microbiol Infect (Epub 25 Sep 2015).
158.
Rasigade JP, Raulin O, Picaud JC, Tellini C, Bes M, Grando J, et al. Methicillin-resistant Staphylococcus capitis with reduced vancomycin susceptibility causes late-onset sepsis in intensive care neonates. PLoS One. 2012;7(2):e31548.PubMedPubMedCentralCrossRef
159.
Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child. 2013;98(6):449–53.PubMedCrossRef
160.
Pawlotsky F, Thomas A, Kergueris MF, Debillon T, Roze JC. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. Br J Clin Pharmacol. 1998;46(2):163–7.PubMedPubMedCentralCrossRef
161.
Samiee-Zafarghandy S, van den Anker JN. Do we really need continuous vancomycin infusion in neonates? Arch Dis Child. 2013;98(12):1023–4.PubMedCrossRef
162.
Madigan T, Teng CB, Koshaish J, Johnson KR, Graner KK, Banerjee R. Optimization of vancomycin dosing in very low-birth-weight preterm neonates. Am J Perinatol. 2015;32(1):83–6.PubMedPubMedCentral
163.
van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755–71.PubMedCrossRef
164.
Yogev R, Damle B, Levy G, Nachman S. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Pediatr Infect Dis J. 2010;29(9):827–30.PubMedCrossRef
165.
Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997;39(6):677–86.PubMedCrossRef
166.
Rao SC, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev. 2011;11:CD005091.PubMed
167.
Skopnik H, Heimann G. Once daily aminoglycoside dosing in full term neonates. Pediatr Infect Dis J. 1995;14(1):71–2.PubMedCrossRef
168.
Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics. 2004;114(1):e111–8.PubMedCrossRef
169.
Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–77.PubMedCrossRef
170.
van Buul LW, Sikkens JJ, van Agtmael MA, Kramer MH, van der Steen JT, Hertogh CM. Participatory action research in antimicrobial stewardship: a novel approach to improving antimicrobial prescribing in hospitals and long-term care facilities. J Antimicrob Chemother. 2014;69(7):1734–41.PubMedCrossRef
171.
Patel S, Landers T, Larson E, Zaoutis T, Delamora P, Paul DA, et al. Clinical vignettes provide an understanding of antibiotic prescribing practices in neonatal intensive care units. Infect Control Hosp Epidemiol. 2011;32(6):597–602.PubMedPubMedCentralCrossRef
172.
Shipp KD, Chiang T, Karasick S, Quick K, Nguyen ST, Cantey JB. Antibiotic stewardship challenges in a referral neonatal intensive care unit. Am J Perinatol (Epub 18 Dec 2015).
Metadaten
Titel
Optimizing the Use of Antibacterial Agents in the Neonatal Period
verfasst von
Joseph B. Cantey
Publikationsdatum
01.04.2016
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 2/2016
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-015-0161-1

Weitere Artikel der Ausgabe 2/2016

Pediatric Drugs 2/2016 Zur Ausgabe

Original Research Article

A Qualitative Study into Dependent Relationships and Voluntary Informed Consent for Research in Pediatric Oncology

Leading Article

Drug Treatment of Heart Failure in Children: Focus on Recent Recommendations from the ISHLT Guidelines for the Management of Pediatric Heart Failure

Short Communication

Long-Term Follow-Up on a Cohort Temporary Utilization Authorization (ATU) Survey of Patients Treated with Pheburane (Sodium Phenylbutyrate) Taste-Masked Granules

Current Opinion

What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK Experience

Therapy in Practice

Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options

Review Article

Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration

Neu im Fachgebiet Pädiatrie

23.04.2024 | Typ-1-Diabetes | Nachrichten

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

22.04.2024 | Fehlsichtigkeit | Nachrichten

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

18.04.2024 | Spinale Muskelatrophien | Nachrichten

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind
weitere anzeigen

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen